1. Introduction {#sec1-molecules-22-01954}
===============

The tetracyclic indoloquinoline ring systems constitute important structural motifs in natural products exhibiting numerous biological activities \[[@B1-molecules-22-01954],[@B2-molecules-22-01954],[@B3-molecules-22-01954]\]. For example, cryptolepine (**I**, indolo\[3,2-*b*\]quinoline) and neocryptolepine (**II**, indolo\[2,3-*b*\]quinoline) are representative alkaloids isolated from the roots of the African plant *Cryptolepis sanguinolenta* \[[@B4-molecules-22-01954],[@B5-molecules-22-01954],[@B6-molecules-22-01954]\] ([Figure 1](#molecules-22-01954-f001){ref-type="fig"}). Notably, an aqueous macerate or decoction of this plant is used in traditional medicine against malaria \[[@B7-molecules-22-01954]\]. These two alkaloids, which only differ in the respective orientation of their indole and quinoline components, display potent antiparasitic properties \[[@B5-molecules-22-01954],[@B8-molecules-22-01954],[@B9-molecules-22-01954],[@B10-molecules-22-01954]\]. Due to the linearly arranged planar tetracyclic structure, cryptolepine (**I**) and neocryptolepine (**II**) are DNA-intercalating agents and inhibit topoisomerase II, showing a high level of cytotoxicity \[[@B11-molecules-22-01954],[@B12-molecules-22-01954],[@B13-molecules-22-01954],[@B14-molecules-22-01954]\].

Our previous structure activity relationship (SAR) study about the antiproliferative activity of the 5-methyl-indolo\[2,3-*b*\]quinoline derivatives revealed that the ω-aminoalkylamino substituent at C11 is an important element for their bioactivity. For example, the 3-aminopropylamino group on **2** (R^1^ = H) could increase the antiproliferative activity against the human leukemia cell line MV4-11 by about 20 times compared to that the of 11-chloro precursor **1** (R^1^ = H) \[[@B15-molecules-22-01954],[@B16-molecules-22-01954]\].

Based on these findings, in this work, we further discuss the effect of the ω-aminoalkylamino substituent at C11 in the 5-methyl-indolo\[2,3-*b*\]quinolone core by diversifying the side-chain structure, i.e., changing the length and branching of the linker between the two nitrogen atoms, etc. We also examine whether a hydroxy group residing on the spacer exerts influence on the antiproliferative activity.

2. Results and Discussion {#sec2-molecules-22-01954}
=========================

2.1. Synthesis {#sec2dot1-molecules-22-01954}
--------------

The synthetic strategy for the 5-methyl-indolo\[2,3-*b*\]quinoline derivatives **2** is based on the nucleophilic aromatic substitution (S~N~Ar) reaction of 11-chloroneocryptolepines **1** with an appropriate amine, as shown in [Figure 2](#molecules-22-01954-f002){ref-type="fig"} \[[@B17-molecules-22-01954]\]. The 11-chloroneocryptolepines **1**, the key intermediates for the diversification, were derived starting with various substituted *N*-methylanilines and methyl-1*H*-indole-3-carboxylates in three steps in good yields \[[@B18-molecules-22-01954]\]. The amination of **1** with various 1,2-diaminoethanes and 1,3-diaminopropanes using an excess amount of dimethyl formamide (DMF), under heating, smoothly yielded the corresponding 11-aminated compounds **2**. Subsequently, a series of ureido derivatives **3** and thioureido derivatives **4** were prepared in high yields by modification of the free terminal amine group of **2** with phenylisocyanate and isothiocyanate in dry CH~2~Cl~2~ at room temperature, respectively \[[@B19-molecules-22-01954]\].

2.2. Biological Evaluation {#sec2dot2-molecules-22-01954}
--------------------------

The natural product neocryptolepine (**II**) is known to exhibit prominent antiproliferative activities, for example, IC~50~ 12.7 ± 1.3 μM against the human (HL-60) leukaemia cell line \[[@B14-molecules-22-01954]\] and IC~50~ 7.48 ± 4.42 μM against the human breast cancer MDA-MB-453 cell line \[[@B20-molecules-22-01954]\], which are comparable with the reference anticancer drug cisplatin (IC~50~ 7.6 ± 0.7 μM). This antiproliferative activity is improved slightly by introduction of the Cl atom at the C11 of neocryptolepine core to IC~50~ 5.16 μM. Introduction of an amino group is expected to increase the cytotoxic activity compared to the non-substituted neocryptolepine. Accordingly, various kinds of amino groups were then evaluated to assess their antiproliferative activity.

The synthesized compounds **2a**--**2n** bearing various ω-aminoalkylamino groups at C11 were tested against the human leukemia MV4-11 cell line while varying substituents R^1^ at C2. As shown in [Table 1](#molecules-22-01954-t001){ref-type="table"}, all assayed compounds were cytotoxic against MV4-11 leukemia cells (IC~50~ values below 0.9 μM), and exhibited higher antiproliferative activities than the reference anticancer drug cisplatin (IC~50~ 2.82 μM), but lower activities than doxorubicin HCl (IC~50~ 0.006 μM).

Amongst compounds **2a**--**2d** bearing a geminal dimethyl group in the pendant on the amino side chain of the three-carbon-atoms spacer, the Cl atom at C2 was favored over the methyl group (i.e., **2c** vs. **2b**) and the Br atom (i.e., **2c** vs. **2d**). However, amongst compounds **2e**--**2g** with a two-carbon-atoms spacer, compound **2f** bearing a methyl group at C2 was more effective than **2g** with a Cl atom at C2. Compound **2j**, bearing only one methyl group in the side chain on the two-carbon-atoms spacer, was more active than **2g** with a geminal methyl group in the side chain. Compounds **2m** and **2n** bearing a Cl or a Br atom at C2, respectively, showed almost the same activity. Amongst the tested compounds, **2h**, modified with a 3-amino-2-hydroxypropylamino group at C11 and a Cl at C2, showed the highest antiproliferative activity (IC~50~ 0.042 μM).

Subsequently, the ureido and thioureido derivatives **3** and **4** were tested for their antiproliferative activity against the human leukemia MV4-11 cell line. Unfortunately, compounds **3** and **4** showed slightly less pronounced antiproliferative activities, compared with compound **2**, bearing a free terminal amino group ([Table 2](#molecules-22-01954-t002){ref-type="table"}).

Compounds **2a**, **2c**, **2f**, **2h**, **2k**, **2m**, and **2n** being of high antiproliferative activity against MV4-11 cells were chosen as candidates for further studies on their antiproliferative activity against non-small cell lung cancer (A549) and colon cancer (HCT116) cell lines, along with normal murine fibroblasts (BALB/3T3). The test results are listed in [Table 3](#molecules-22-01954-t003){ref-type="table"}. All tested compounds showed higher antiproliferative activities against the cancer cells than the cisplatin used as a control agent. Compounds **2k** and **2h** showed higher activity against the A549 and HCT116 cell line than other compounds, and they showed selective antiproliferative activity against the MV4-11 cell line. The 2-bromo-derivative **2n** and the 2-chloro-derivative **2m** showed almost the same cytotoxicity against A549 and HCT116 cell lines compared to the normal cell line BALB/3T3, but **2n** showed potent activity against the MV4-11 cell line with an IC~50~ value of 0.078 μM. Compounds **2c** and **2f** showed lower cytotoxicity against the normal cell line, and moderate activity against the A549 and HCT116 cell lines. It is quite obvious that the introduction of proper alkylamino substituents into biologically active derivatives can favourably influence their activities and selectivities in DNA binding.

2.3. Spectroscopic Characterization of Neocryptolepine Derivative ***2d*** Interacting with Salmon Sperm DNA {#sec2dot3-molecules-22-01954}
------------------------------------------------------------------------------------------------------------

The DNA binding studies of compound **2d** were performed using UV-Vis absorption spectroscopy with salmon sperm DNA in a phosphate buffer of pH 7.0 at 20 °C. A red shift and a hypochromic effect were observed in the absorption spectra while the DNA solution was gradually added to the solution of compound **2d**. The results depleted in [Figure 3](#molecules-22-01954-f003){ref-type="fig"}a showed that the minimum of the absorption band at 256 nm for **2d** decreased while increasing the DNA concentration. The maximum absorption shifted from 256 nm to 289 nm. This illustrated that the mode of **2d** binding to DNA was intercalation. The binding constant of **2d** to DNA was calculated as 4.12 × 10^5^ L·mol^−1^, according to a double-reciprocal equation.

3. Experimental {#sec3-molecules-22-01954}
===============

3.1. Chemistry {#sec3dot1-molecules-22-01954}
--------------

The commercially obtained reagents (TCI, Tokyo, Japan) were used directly without further purification. The ^1^H-NMR and ^13^C-NMR spectra were taken on Varian INOVA-600, Varian INOVA-400, Varian INOVA-300 (Palo Alto, CA, USA), or Bruker 400 spectrometers (Billerica, MA, USA), using CDCl~3~ or DMSO-*d*~6~ as a solvent and tetramethylsilane (TMS) as the internal standard. The NMR spectra of the compounds are in [Supplementary Materials](#app1-molecules-22-01954){ref-type="app"}. Mass spectra were obtained on a Bruker microTOF II-SKA spectrometer. The melting points were determined on a RFS-10 hot stage microscope (J-Science, Kyoto, Japan). The UV spectra were recorded with a U-2910 spectrophotometer (Hitachi, Tokyo, Japan) in a 1 cm path length quartz cuvette at an indicated wavelength, and the sample was dissolved in phosphate buffer with 2.5% DMSO.

### 3.1.1. General Procedure for the Synthesis of 11-Aminoneocryptolepines **2a**--**2n** {#sec3dot1dot1-molecules-22-01954}

11-Chloroindoloquinolines **1** (0.3 mmol) and an excess of the appropriate ω-aminoalkylamine (3.0 mmol) were heated together at 120 °C for 4 h. Thin Layer Chromatography (TLC) monitoring was used to ensure the completion of the reaction. The resulting brown crude oil was purified by flash chromatography using AcOEt/2 M ammonia in MeOH (9:1, *v*/*v*) as an eluent to yield pure yellowish solid products.

*N-(3-Amino-2,2-dimethylpropyl)-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2a**. Yellowish solid. Yield: 84%. M.p. 112--114 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.18 (dd, *J* = 8.0, 4.0 Hz, 1H), 8.00 (d, *J* = 8.0 Hz, 1H), 7.76 (d, *J* = 8.0 Hz, 1H), 7.69--7.61 (m, 2H), 7.40 (t, *J* = 8.0 Hz, 1H), 7.32--7.28 (t, *J* = 8.0 Hz, 1H), 7.16 (t, *J* = 8.0 Hz, 1H), 4.23 (s, 3H), 3.85 (s, 2H), 2.86 (s, 2H), 0.90 (s, 6H). ^13^C-NMR (100 MHz, CDCl~3~): δ = 157.1, 152.2, 149.2, 138.1, 130.0, 125.0, 124.4, 121.7, 120.3, 118.5, 117.1, 116.1, 114.6, 105.0, 61.2, 53.0, 36.0, 32.7, 23.6 (2C). HRMS (ESI): *m*/*z* = 331.4462 \[M − H\]^−^, calcd. 332.4421.

*N-(3-Amino-2,2-dimethylpropyl)-2,5-dimethyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2b**. Yellowish solid. Yield: 86 % M.p. 173--175 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.01 (br s, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 7.57--7.50 (m, 2H), 7.39 (t, *J* = 8.0 Hz, 1H), 7.14 (t, *J* = 8.0 Hz, 1H), 4.24 (s, 3H), 3.84 (s, 2H), 2.87 (s, 2H), 2.53 (s, 3H) 0.95 (s, 6H). ^13^C-NMR (100 MHz, CDCl~3~): δ = 149.0, 136.4, 131.4, 129.6, 125.1, 124.4, 123.9, 121.5, 118.3, 117.2, 116.0, 114.5, 106.0, 60.6, 52.8, 36.1, 32.6, 23.6 (2C), 21.1. HRMS (ESI): *m*/*z* = 347.2204 \[M + H\]^−^, calcd. 347.2236.

*N-(3-Amino-2,2-dimethylpropyl)-2-chloro-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2c**. Yellowish solid. Yield: 95%. M.p. 177--179 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.20 (s, 1H), 7.97(d, *J* = 8 Hz, 1H), 7.76 (d, *J* = 8 Hz, 1H), 7.60--7.56 (m, 2H), 7.41 (m, 1H), 7.18 (m, 1H), 4.22 (s, 3H), 3.85 (s, 2H), 2.92 (s, 2H), 0.90 (s, 6H). ^13^C-NMR (100 MHz, CDCl~3~): δ = 148.4, 136.8, 130.4 (2C), 126.3, 125.7 (2C), 124.7, 124.0 (2C), 122.4 (2C), 119.2, 117.5, 116.3, 62.0, 53.4, 36.0, 33.4, 24.0 (2C). HRMS (ESI): *m*/*z* = 365.1624 \[M − H\]^−^, calcd. 366.1611.

*N-(3-Amino-2,2-dimethylpropyl)-2-bromo-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2d**. Yellowish solid. Yield: 86%. M.p. 184--186 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 7.97 (q, *J* = 7.8 Hz, 2H), 7.76 (d, *J* = 7.8 Hz, 1H), 7.55 (q, *J* = 7.2 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.26 (t, *J* = 5.4 Hz, 1H), 7.19 (t, *J* = 7.8 Hz, 1H), 4.06 (s, 3H), 3.66 (s, 2H), 2.68 (s, 2H), 0.76 (s, 6H). ^13^C-NMR (75 MHz, CDCl~3~): δ = 157.1, 152.4, 148.0, 136.8, 132.7, 126.7, 125.4, 124.8, 122.5, 118.9, 117.7, 117.4, 116.3, 113.3, 104.6, 62.0, 53.2, 35.7, 33.1, 23.9 (2C).

*N-(2-Amino-2-methylpropyl)-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2e**. Yellowish solid. Yield: 92%. M.p. 130--132 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.24 (d, *J* = 8.0 Hz, 1H), 8.14 (d, *J* = 4.0 Hz, 1H), 7.80--7.71 (m, 3H), 7.43--7.41 (m, 1H), 7.33 (m, 1H), 7.01 (d, *J* = 8.0 Hz, 1H), 4.28 (s, 3H), 3.68 (S, 2H), 1.13 (s, 6H). ^13^C-NMR (100 MHz, CDCl~3~): δ = 156.8, 152.6, 149.5, 138.7, 130.6, 125.7, 125.1, 124.6, 121.5, 120.6, 119.2, 117.5, 115.8, 115.0, 106.9, 59.4, 51.6, 33.0, 29.4 (2C). HRMS (ESI): *m*/*z* = 319.1911 \[M + H\]^−^, calcd. 319.1923.

*N-(2-Amino-2-methylpropyl)-2,5-dimethyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2f**. Yellowish solid. Yield: 88 %. M.p. 132--134 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.13 (d, *J* = 7.6 Hz, 1H), 7.95 (s, 1H), 7.76 (d, *J* = 8.0 Hz, 1H), 7.53 (q, *J* = 8.0 Hz, 2H), 7.42 (t, *J* = 8.0 Hz, 1H), 7.19 (t, *J* = 7.6 Hz, 1H), 6.71 (s, 1H), 4.23 (s, 3H), 3.64 (d, *J* = 8.0 Hz, 2H), 2.55 (s, 3H), 1.10 (s, 6H). ^13^C-NMR (101 MHz, CDCl~3~): δ = 157.0, 153.0, 149.6, 137.0, 132.1, 130.2, 125.8, 124.7 (2C), 124.6, 121.6, 119.0, 117.5, 116.1, 115.1, 59.7, 51.9, 33.1, 29.6 (2C), 21.7. HRMS (ESI): *m*/*z* = 333.2054 \[M + H\]^−^, calcd. 333.2079.

*N-(2-Amino-2-methylpropyl)-2-chloro-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2g**. Yellowish solid. Yield: 90%. M.p. 108--110 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.15 (q, *J* = 7.6, 2H), 7.76 (d, *J* = 8.0 Hz, 1H), 7.62 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.21 (t, *J* = 7.6 Hz, 1H), 6.73 (br, 1H), 4.22 (s, 3H), 3.58 (d, *J* = 4.5 Hz, 2H), 1.11 (s, 6H). ^13^C-NMR (101 MHz, CDCl~3~): δ = 156.4, 152.9, 148.2, 137.1, 130.4, 126.1, 125.9, 124.5, 124.4, 121.6, 119.4, 117.6, 116.8, 116.4, 107.6, 59.1, 51.5, 33.1, 29.5 (2C). HRMS (ESI): *m*/*z* = 351.1422 \[M − H\]^−^, calcd. 352.1455.

*1-Amino-3-(2-chloro-5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)propan-2-ol* **2h**. Yellowish solid. Yield: 82%. M.p. 150--152 °C. ^1^H-NMR (400 MHz, DMSO-*d*~6~): δ = 8.56 (s, 1H), 7.95 (d, *J* = 7.6 Hz, 1H), 7.85 (d, *J* = 9.2 Hz, 1H), 7.78 (q, *J* = 4 Hz, 1H), 7.50 (d, *J* = 8 Hz, 1H), 7.28 (t, *J* = 8 Hz, 1H), 7.07 (q, *J* = 8 Hz, 1H), 4.13 (s, 3H), 3.91--3.87 (m, 1H), 3.79 (dd, *J* = 12.8, 6.5 Hz, 2H), 3.69--3.66 (m, 2H). ^13^C-NMR (101 MHz, DMSO-*d*~6~): δ = 156.1, 152.4, 147.5, 136.1, 130.1, 124.9 (2C), 123.9, 123.4, 122.2, 118.1, 117.0, 116.7, 116.6, 105.4, 70.9, 52.3, 45.4, 32.3. HRMS (ESI): *m*/*z* = 354.1247 \[M − H\]^−^, calcd. 353.11275.

*1-Amino-3-(2-bromo-5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)propan-2-ol* **2k**. Yellowish solid. Yield: 76%. M.p. 162--164 °C. ^1^H-NMR (400 MHz, DMSO-*d*~6~): δ = 8.67 (s, 1H), 7.94 (t, *J* = 8.0 Hz, 2H), 7.81 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 8.0, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.11 (t, *J* = 8.0 Hz, 1H), 4.13 (s, 3H), 3.87--3.82 (m, 1H), 3.81 (dd, *J* = 12.0, 6.5 Hz, 2H), 3.68--3.65 (m, 2H). ^13^C-NMR (101 MHz, DMSO-*d*~6~): δ = 156.1, 152.4, 147.5, 136.4, 132.8, 126.3 (2C), 124.9, 123.9, 122.2, 118.2, 117.3, 116.7, 112.7, 105.2, 70.9, 52.3, 45.4, 32.3.

*N-(2-Aminopropyl)-2-chloro-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2m**. Yellowish solid. Yield: 87%. M.p. 95--79 °C. ^1^H-NMR (600 MHz, CDCl~3~): δ = 8.10 (d, *J* = 6 Hz, 2H), 7.76 (d, *J* = 7.8 Hz, 1H), 7.59 (t, *J* = 6.6 Hz, 1H), 7.54 (d, *J* = 9.1 Hz, 1H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.22 (t, *J* = 7.2 Hz, 1H), 6.48 (br, 1H), 4.20 (s, 3H), 3.79 (d, *J* = 11.4 Hz, 1H), 3.40 (t, *J* = 10.8 Hz, 1H), 3.12 (q, *J* = 6 Hz, 1H), 1.10 (d, *J* = 6.2 Hz, 3H). ^13^C-NMR (151 MHz, CDCl~3~): δ = 156.3, 152.8, 147.9, 137.0, 130.4, 126.2, 125.9, 124.5, 124.3, 121.5, 119.4, 117.6, 116.9, 116.3, 108.1, 55.1, 47.9, 33.1, 22.9. HRMS (ESI): *m*/*z* = 337.1232 \[M − H\]^−^, calcd. 338.1298.

*N-(2-Amino-2-methylpropyl)-2-bromo-5-methyl-5H-indolo\[2,3-b\]quinolin-11-amine* **2n**. Yellowish solid. Yield: 90%. M.p. 101--103 °C. ^1^H-NMR (600 MHz, CDCl~3~): δ = 8.21 (s, 1H), 8.08 (d, *J* = 7.8 Hz, 1H), 7.74 (d, *J* = 7.8 Hz, 1H), 7.71 (q, *J* = 6 Hz, 1H), 7.48--7.43 (m, 2H), 7.20 (t, *J* = 7.8 Hz, 1H), 6.46 (s, 1H), 4.15 (s, 3H), 3.74 (d, *J* = 11.4 Hz, 1H), 3.37 (dd, *J* = 7.8, 7.8 Hz, 1H), 3.11--3.08 (m, 1H), 1.09 (d, *J* = 6.0 Hz, 3H). ^13^C-NMR (75 MHz, CDCl~3~): δ = 156.1, 152.6, 147.8, 137.3, 133.1, 127.5, 127.2, 126.2, 124.2, 121.5, 119.4, 117.6, 116.6, 113.3, 108.0, 55.1, 47.9, 33.2, 22.9.

### 3.1.2. General Procedure for the Synthesis of **3a**--**3d** and **4a**,**b** {#sec3dot1dot2-molecules-22-01954}

2-Substituted 5-methyl-5*H*-indolo\]2,3-*b*\]quinolone-11-amine (**2**) (50 mg) was dissolved in dry CH~2~Cl~2~ (1 mL), and a solution of phenylisocyanate or phenylisothiocyanate (1.1 equiv.) in dry CH~2~Cl~2~ (1 mL) was added drop by drop under stirring at room temperature for 2--4 h. TLC monitoring was used to ensure the completion of the reaction. The reaction mixture was evaporated to dryness under reduced pressure. The crude product was purified by flash chromatography using AcOEt/2M ammonia in MeOH (9:1, *v*/*v*) as an eluent to yield pure products as yellowish solids.

*1-(2,2-Dimethyl-3-(5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)propyl)-3-phenylurea* **3a**. Yellowish solid. Yield: 91%. M.p. 154--156 °C. ^1^H-NMR (600 MHz, CDCl~3~): δ = 9.25 (s, 1H), 8.42 (d, *J* = 6 Hz, 1H), 7.74--7.70 (m, 2H), 7.64 (d, *J* = 6 Hz, 1H), 7.46 (s, 2H), 7.40--7.35 (m, 2H), 7.24--7.22 (m, 2H), 7.14 (s, 1H), 6.97 (s, 1H), 6.77 (s, 1H), 6.64 (s, 1H), 4.03 (s, 3H), 3.60 (s, 2H), 3.25 (s, 2H), 2.29 (br, 1H), 0.63 (s, 6H). ^13^C-NMR (151 MHz, CDCl~3~): δ = 158.0, 157.1, 151.5, 149.6, 140.0, 137.9, 130.9, 129.5 (2C), 126.0, 124.4, 124.2, 123.1, 122.6, 121.9, 120.0 (2C), 119.7, 116.9, 116.5, 115.0, 106.8, 55.7, 48.0, 38.6, 33.3, 24.0 (2C). HRMS (ESI): *m*/*z* = 450.2364 \[M − H\]^−^, calcd. 451.2372.

*1-(3-(2,5-Dimethyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)-2,2-dimethylpropyl)-3-phenylurea* **3b**. Yellowish solid. Yield: 83%. M.p. 228--230 °C. ^1^H-NMR (300 MHz, CDCl~3~): δ = 9.18 (s, 1H), 8.12 (s, 1H), 7.67 (d, *J* = 7.8 Hz, 1H), 7.57 (d, *J* = 7.8 Hz, 1H), 7.45 (d, *J* = 9 Hz, 3H), 7.34 (q, *J* = 6 Hz, 2H), 7.23 (d, *J* = 9 Hz, 2H), 7.08 (t, *J* = 9 Hz, 1H), 6.98 (t, *J* = 6 Hz, 1H), 6.49 (s, 1H), 6.10 (s, 1H), 3.97 (s, 3H), 3.52 (d, *J* = 6.6 Hz, 2H), 3.35 (d, *J* = 6.2 Hz, 2H), 2.58 (s, 3H), 0.77 (s, 6H). ^13^C-NMR (101 MHz, CDCl~3~): δ = 157.9, 156.4, 150.7, 149.7, 140.3, 136.0, 132.5, 131.6, 129.4 (2C), 125.9, 124.2 (2C), 124.0, 122.8, 122.6, 119.6 (2C), 116.8, 116.2, 114.9, 106.5, 55.7, 48.0, 38.6, 33.3, 24.1(2C), 21.7. HRMS (ESI): *m*/*z* = 466.4585 \[M + H\]^−^, calcd. 466.2607.

*1-(3-(2-Chloro-5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)-2,2-dimethylpropyl)-3-phenylurea* **3c**. Yellowish solid. Yield: 84%. M.p. 232--234 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ = 8.36 (s, 1H), 8.13 (br, 1H), 7.73--7.70 (m, 2H), 7.60--7.57 (m, 1H), 7.45--7.39 (m, 3H), 7.39 (t, *J* = 7.4 Hz, 1H), 7.14--7.06 (m, 2H), 7.31 (t, *J* = 7.2 Hz, 2H), 6.53 (br, 1H), 5.91 (br, 1H), 4.11 (s, 3H), 3.57 (d, *J* = 6.4 Hz, 2H), 3.31 (d, *J* = 6.0 Hz, 2H), 0.73 (s, 6H). ^13^C-NMR (101 MHz, CDCl~3~): δ = 157.7, 156.8, 148.2, 139.7, 136.4, 130.9, 129.7 (2C), 127.3, 126.6, 124.0 (2C), 123.9, 123.7, 122.6, 120.6 (2C), 120.0, 117.9, 116.9, 116.4, 106.8, 55.9, 48.3, 38.4, 33.4, 24.1 (2C). HRMS (ESI): *m*/*z* = 484.1918 \[M − H\]^−^, calcd. 485.1982.

*1-(2-Methyl-1-(5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)propan-2-yl)-3-phenylurea* **3d**. Yellowish solid. Yield: 89%. M.p. 175--177 °C. ^1^H-NMR (600 MHz, CDCl~3~): δ = 8.88 (br, 1H), 8.31 (s, 1H), 7.73 (dd, *J* = 7.2, 7.2 Hz, 2H), 7.51 (t, *J* = 12 Hz, 4H), 7.37 (d, *J* = 8.4 Hz, 2H), 7.30 (t, *J* = 7.4 Hz, 2H), 7.10 (t, *J* = 7.2 Hz, 1H), 7.04 (t, *J* = 7.0 Hz, 1H), 6.05 (s, 1H), 4.07 (s, 3H), 3.77 (s, 2H), 1.17 (s, 6H). ^13^C-NMR (151 MHz, CDCl~3~): δ = 157.2, 156.9, 151.9, 148.7, 139.8, 136.5, 130.9, 129.6 (2C), 129.5, 127.1, 126.2, 124.3, 123.3, 122.3, 119.9 (2C), 119.7, 117.4, 117.0, 116.3, 106.4, 60.1, 54.6, 33.4, 26.3 (2C).

*1-(2,2-Dimethyl-3-(5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)propyl)-3phenylthiourea* **4a**. Yellowish solid. Yield: 90%. M.p. 172--174 °C. ^1^H-NMR (600 MHz, CDCl~3~): δ = 8.54 (d, *J* = 6 Hz, 1H), 7.86 (d, *J* = 6.0 Hz, 1H), 7.76 (dd, *J* = 7.8, 7.2 Hz, 2H), 7.66 (d, *J* = 7.8 Hz, 1H), 7.46 (t, *J* = 6.0 Hz, 1H), 7.39 (dd, *J* = 9, 7.2 Hz, 3H), 7.32 (d, *J* = 6.0 Hz, 2H), 7.25--7.19 (m, 1H), 6.89 (s, 1H), 4.24 (s, 3H), 3.79 (d, *J* = 6.0 Hz, 2H), 3.73 (d, *J* = 6.0 Hz, 2H), 1.96 (br, 1H), 0.71 (s, 6H). ^13^C-NMR (151 MHz, CDCl~3~): δ = 182.5, 153.4, 151.0, 145.5, 138.5, 137.4, 132.0, 129.5 (2C), 126.4, 126.24, 125.2 (2C), 125.0, 123.3, 123.1, 122.7, 121.1, 117.1, 115.4, 115.1, 103.5, 54.7, 51.8, 39.2, 34.6, 24.3 (2C). HRMS (ESI): *m*/*z* = 466.2170 \[M − H\]^−^, calcd. 467.2144.

*1-(1-(2-Chloro-5-methyl-5H-indolo\[2,3-b\]quinolin-11-ylamino)-2-methylpropan-2-yl)-3-phenylthiourea* **4b**. Yellowish solid. Yield: 84%. M.p. 147--149 °C. ^1^H-NMR (600 MHz, CDCl~3~): δ = 8.43 (s, 1H), 8.09 (s, 1H), 7.81 (d, *J* = 7.2 Hz, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.59--7.56 (m, 1H), 7.48 (d, *J* = 12 Hz, 1H), 7.38 (t, *J* = 7.6 Hz, 1H), 7.33--7.29 (m, 2H), 7.22 (t, *J* = 7.5 Hz, 1H), 7.11 (dd, *J* = 12.9, 7.5 Hz, 3H), 6.13 (s, 1H), 5.88 (s, 1H), 4.41 (d, *J* = 5.5 Hz, 2H), 4.06 (s, 3H), 1.22 (s, 6H). ^13^C-NMR (151 MHz, CDCl~3~): δ = 180.6, 156.5, 152.8, 147.9, 136.8 (d), 130.8, 130.4, 127.6, 126.8, 126.6, 125.5 (2C), 124.5, 124.4, 123.9, 121.7, 118.4, 117.6, 117.1, 116.6, 109.1, 60.8, 58.7, 55.5, 33.3, 26.7 (2C).

3.2. Antitumor Screening Test {#sec3dot2-molecules-22-01954}
-----------------------------

Anti-proliferative assays in vitro were performed in the same manner as described in the literature \[[@B15-molecules-22-01954],[@B16-molecules-22-01954],[@B21-molecules-22-01954],[@B22-molecules-22-01954]\]. The cell lines of human leukemia MV4-11, lung A549, and colon HCT 116 cancer were chosen as representing various tissue origins and BALB/3T3 normal murine fibroblasts to assess the cytotoxicity of tested compounds towards normal cells. The IC~50~ parameter (half-maximum inhibitory concentration) was calculated based on sulforhodamine B (HCT-116, A549, BALB/3T3) or MTT (MV4-11) assay results after 72 h of exposure \[[@B15-molecules-22-01954],[@B16-molecules-22-01954]\]. Each compound in a given concentration was tested in triplicate in each experiment, which was repeated three to five times.

A lot of new chemicals undergo screening in various cell cultures but eventually do not achieve drug status due to severe side-effects. As Badisa et al. note: "Ideally, one of the criteria for a drug being good is that it should not exhibit any undesirable side-effects on normal cells" \[[@B23-molecules-22-01954]\]. Therefore, to improve the search for new, not or significantly less toxic to normal mammalian cells compounds, the introduction of normal cells and a comparison of the cytotoxicity of tested compounds with cancer cells in early drug-screening protocols is valuable. Moreover, the BALB/3T3 fibroblasts used in our studies are recommended by various agencies introducing alternative methods for testing the toxicity of compounds. For example, these cells are used in some methods aiming to estimate starting doses for the oral acute systemic toxicity of compounds under the European Center of Validation of Alternative Methods (ECVAM) guidelines (OECD guidance document (GD) 129 published in 2010).

4. Conclusions {#sec4-molecules-22-01954}
==============

In conclusion, we have prepared a series of 11-substituted neocryptolepines with branched ω-aminoalkylamino chains of different linker lengths between the two nitrogen atoms, and their antiproliferative activities were evaluated using the MV4-11 (human leukemia), A549 (human lung cancer), HCT116 (human colon cancer), and normal mouse fibroblast (BALB/3T3) cell lines. All synthesized compounds showed potent in vitro antiproliferative activity against the MV4-11 cell line over the 11-chloro substituted precursors. As a result of the diversification of the ω-aminoalkylamino chains, we found the highest antiproliferative activity for 11-(3-amino-2-hydroxy)propylamino-substituted compounds **2h** and **2k,** showing mean IC~50~ values of 0.042 μM and 0.057 μM against MV4-11 cells, 0.197 μM and 0.1988 μM against A549 cells, and 0.138 μM and 0.117 μM against BALB/3T3 cells, respectively. The modification of ω-aminoalkylamino chains to ω-ureido and -thioureido derivatives was not the case for the improved activity. Further variations in substituents and their pattern may be necessary to obtain better activity.
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![Chemical structures of indoloquinolines from Cryptolepis sanguinolenta.](molecules-22-01954-g001){#molecules-22-01954-f001}

![Synthesis of 11-aminoalkylamino-5-methyl-indolo\[2,3-*b*\]quinolines **2** and their ureido and thioureido derivatives **3** and **4**.](molecules-22-01954-g002){#molecules-22-01954-f002}

![(**a**) UV-Vis absorption spectra of compound **2d** at 20 °C. C(**2d**) = 50 μmol/L, C(DNA) = 0.0, 0.025, 0.05, 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25 μmol/L for curves 1--11 in phosphate buffer solution (pH 7.0) (**b**) Plot of 1/ΔA vs. 1/\[DNA\] for **2d**-DNA.](molecules-22-01954-g003){#molecules-22-01954-f003}

molecules-22-01954-t001_Table 1

###### 

Antiproliferative activity of 11-aminoalkylamino-5-methyl-indolo\[2,3-*b*\]quinolines against the human leukemia MV4-11 cell line.

  Compound          R^1^   C11-Substituent                    Yield, % of Amination   IC~50~ (μM)
  ----------------- ------ ---------------------------------- ----------------------- ---------------
  Cisplatin                \-                                                         2.820 ± 0.450
  Doxorubicin HCl          \-                                 \-                      0.006 ± 0.002
  **1a**            H      Cl                                 \-                      1.312 ± 0.262
  **1b**            Br     Cl                                 \-                      0.810 ± 0.145
  **2a**            H      ![](molecules-22-01954-i001.jpg)   84                      0.150 ± 0.060
  **2b**            Me     ![](molecules-22-01954-i002.jpg)   86                      0.288 ± 0.075
  **2c**            Cl     ![](molecules-22-01954-i003.jpg)   95                      0.119 ± 0.043
  **2d**            Br     ![](molecules-22-01954-i004.jpg)   86                      0.308 ± 0.102
  **2e**            H      ![](molecules-22-01954-i005.jpg)   92                      0.392 ± 0.188
  **2f**            Me     ![](molecules-22-01954-i006.jpg)   88                      0.105 ± 0.027
  **2g**            Cl     ![](molecules-22-01954-i007.jpg)   90                      0.453 ± 0.209
  **2h**            Cl     ![](molecules-22-01954-i008.jpg)   82                      0.042 ± 0.014
  **2k**            Br     ![](molecules-22-01954-i009.jpg)   76                      0.057± 0.015
  **2m**            Cl     ![](molecules-22-01954-i010.jpg)   87                      0.103 ± 0.014
  **2n**            Br     ![](molecules-22-01954-i011.jpg)   90                      0.078 ± 0.020

The IC~50~ value is defined as the concentration of a compound that corresponds to a 50% growth inhibition. Data are expressed as the mean ± SD.

molecules-22-01954-t002_Table 2

###### 

Antiproliferative activity of the neocryptolepine derivatives **3a**--**3d**, **4a**, and **4b** against the human leukemia MV4-11 cell line.

  Compound   n   R^1^   R^2^   R^3^   Yield, %   IC~50~ (μM)
  ---------- --- ------ ------ ------ ---------- ---------------
  **3a**     1   H      Me     Me     91 ^a^     0.549 ± 0.108
  **3b**     1   Me     Me     Me     83 ^a^     0.427± 0.092
  **3c**     1   Cl     Me     Me     84 ^a^     0.790 ± 0.302
  **3d**     0   H      Me     Me     89 ^a^     0.464 ± 0.141
  **4a**     1   H      Me     Me     90 ^b^     0.680 ± 0.215
  **4b**     0   Cl     Me     Me     84 ^b^     2.330 ± 1.015

^a^ Yield of ureidation of the precursor amine **2**; ^b^ Yield of thioureidation of the precursor amine **2**. The IC~50~ value is defined as the concentration of a compound that corresponds to a 50% growth inhibition. Data are expressed as the mean ± SD.

molecules-22-01954-t003_Table 3

###### 

Antiproliferative activity of 11-alkylaminated 5-methyl-indolo\[2,3-*b*\]quinolines against normal mice fibroblasts BALB/3T3 and against the cancer cell lines A549 and HCT 116.

  Compound          BALB/3T3 IC~50~ (μM)   A 549 IC~50~ (μM)   HCT 116 IC~50~ (μM)
  ----------------- ---------------------- ------------------- ---------------------
  Cisplatin         8.700 ± 0.097          9.870 ± 2.400       8.500 ± 0.540
  Doxorubicin HCl   1.078 ± 0.033          0.329 ± 0.097       0.390 ± 0.098
  **2a**            4.789 ± 2.018          1.512 ± 0.198       1.262 ± 0.361
  **2c**            9.131 ± 0.844          1.455 ± 0.168       1.373 ± 0.351
  **2f**            10.558 ± 0.330         1.795 ± 0.270       2.370 ± 0.481
  **2h**            0.896 ± 0.042          0.197 ± 0.028       0.138 ± 0.050
  **2k**            0.864 ± 0.015          0.190 ± 0.027       0.117 ± 0.055
  **2m**            1.018 ± 0.017          1.269 ± 0.118       1.204 ± 0.283
  **2n**            0.939 ± 0.018          0.988 ± 0.164       0.842 ± 0.367

The IC~50~ value is defined as the concentration of a compound that corresponds to a 50% growth inhibition. Human lung cancer cell line (A-549); human colon adenocarcinoma cell line (HCT 116); normal murine embryonic fibroblast cell line (BALB/3T3). Data are expressed as the mean ± SD.
